retatrutide clinical trial news Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 for treatment of type 2 diabetes Retatrutide—A Game Changer in Obesity
Description
Most users experience bloating, gas, or temporary digestive changes during the initial adjustment period
Without careful dietary support, you may lose lean muscle mass, not just fat
Behaviour Research and Therapy, 41(5), 509-528
Others report reducing their dosage to save money
No significant increase in the risk of malignancy was observed
According to CDC estimates, 80% of US adults with prediabetes are undiagnosed and unaware
